|1.||Chatelut, Etienne: 2 articles (11/2008 - 10/2006)|
|2.||Vassal, Gilles: 2 articles (11/2008 - 10/2006)|
|3.||Delbaldo, Catherine: 2 articles (11/2008 - 10/2006)|
|4.||Séronie-Vivien, Sophie: 2 articles (11/2008 - 10/2006)|
|5.||Khemani, L: 2 articles (06/2002 - 03/2002)|
|6.||Hayes, M: 2 articles (06/2002 - 03/2002)|
|7.||Tse, F: 2 articles (06/2002 - 03/2002)|
|8.||Bakhtiar, R: 2 articles (06/2002 - 03/2002)|
|9.||Mestan, Jürgen: 1 article (06/2013)|
|10.||Aichholz, Reiner: 1 article (06/2013)|
|1.||Body Weight (Weight, Body)
11/01/2008 - "The apparent clearance of CGP74588 was similarly dependent on both body weight and AGP and significantly lower (30% reduction) at steady-state. "
11/01/2008 - "Plasma imatinib and CGP74588 concentrations observed on day 1 and at steady-state were analyzed by a population pharmacokinetic method (NONMEM) to evaluate the effect of age, body weight, age, sex, albuminemia, plasma alpha1-acid glycoprotein (AGP), and eight polymorphisms corresponding to ABCB1, ABCG2, CYP3A4, CYP3A5, and AGP (pharmacogenetic data available for 46 of 67 patients). "
|2.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
|3.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/01/2013 - "Imatinib, a front-line therapy for both chronic myeloid leukemia and of gastrointestinal stromal tumours, is often substantially metabolised via N-demethylation to the significantly less active CGP74588. "
07/01/2011 - "Our results indicate that CGP74588 could hardly positively contribute to the treatment of chronic myeloid leukemia (CML) where ABCB1 gene overexpression represents a possible mechanism of resistance to imatinib in vivo."
07/01/2006 - "Liquid chromatography-mass spectrometry was used to quantitate imatinib and its metabolite CGP74588 in the plasma and jejunostomy output of a patient with newly diagnosed chronic myelogenous leukemia. "
07/01/2006 - "Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome."
02/01/2009 - "Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias."
06/15/2002 - "Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry."
03/05/2002 - "High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry."
|5.||Short Bowel Syndrome
|2.||ATP-Binding Cassette Transporters (ABC Transporters)
|2.||Renal Dialysis (Hemodialysis)